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Introduction
• Page 5, last paragraph: please correct typo -at FiO2 = 1.0 (not at FiO2 = 1.) Patient eligibility • Page 8 and 9: I would suggest the investigators to add termination or withdrawal criteria for patient safety issue Trial intervention • The investigators should provide more information regarding the HFNC device and standard oxygen device. In addition, HFNC device in the market can generate the maximum flow rate of 60 LPM but they are going to use flow rate at 70 LPM in this study. Is this the new device? • Who will perform endotracheal intubation (attending physician, trainee, etc)?
• They should explain more details regarding how to manage patient who develop desaturation during the study protocol? When to perform face mask ventilation? When to terminate the protocol? Because one of the main objective of the study is the number (or time) of manual FMV and this should have some standard criteria to initiate FMV.
• I am aware that patient who receive standard face mask for ETI under laryngoscopy will develop hypoxemia because the face mask will be removed and patient will not get any oxygen during such period. Outcome • Page 13: In terms of severe complication please clarify the definition of severe desaturation that < 90% or < 80%? • Page 14: please check the definition of desaturation in the section of morbidity in the PACU whether it is defined < 90% or < 80%.
REVIEWER
Jörn Grensemann Universitatsklinikum Hamburg-Eppendorf, Intensive Care REVIEW RETURNED 10-Nov-2018
GENERAL COMMENTS
The planned study compares the preoxygenation by standard face-mask or high-flow-nasal-cannula in patients with predicted difficult intubation in an elective anesthesia setting. This is a very interesting question that certainly needs to be studied since it may have great impact on routine clinical practice with the potential to improve patients' safety for predicted difficult intubation. The study protocol is concisely written and covers all aspects necessary to duplicate the study.
However, I have some remarks. Unfortunately, the study seems to be recruiting patients already so that an amendment of the study protocol is probably not feasible anymore.
As far as I understand the protocol, the "standard" group receives preoxygenation with a non-rebreather mask with 15 L/min O2? By this method, a FiO2 of 1.0 cannot be delivered for preoxygenation and this method may not reflect the routine clinical practice with a half-closed rebreathing anesthesia circuit. In my opinion, the delivery of a FiO2 of 1.0 is mandatory especially in predicted difficult intubation. Please discuss why no anesthesia circuit is used in your study.
Please explain how the sample size calculation allows for the prespecified sub-group analysis. Is it possible to amend the planned sample size after the interim analysis, should the achieved power prove to small? Q2) Please, replace face mask instead of standard device in title. R2) Thank you for this remark, the title was modified as suggested (Line 4 page 1) Q3) Please, add indication of FMV in article. R3) Thank you for this comment, FMV has been removed from the manuscript since it was not a usual abbreviation. This term has been replaced by "Face mask ventilation" throughout the manuscript.
Q4) Please, define primary and secondary outcome correctly. R4) Thank you. We agree that the definitions of the primary and secondary outcomes were not precise enough. This could have been deleterious for further publication an for the clarity of the study design. Moreover, some secondary criteria were missing. As required the primary and secondary outcome were described more precisely as follows: ( Q2) Page 8 and 9: I would suggest the investigators to add termination or withdrawal criteria for patient safety issue R2) Thank you for your comment, we inserted a statement in this section as follows (Lines 19-20, page 14): All of the expected or unexpected adverse events (occurring from the beginning of the preoxygenation to the discharge of the PACU) will be collected in the e-CRF.
Trial intervention Q3) The investigators should provide more information regarding the HFNC device and standard oxygen device. In addition, HFNC device in the market can generate the maximum flow rate of 60 LPM but they are going to use flow rate at 70 LPM in this study. Is this the new device? R3) Thank you for your comment. We added details regarding the 2 standards face mask (for RSi or FOI) and the HFNC as well, as follows (From Line 21, page 8 to line 12 page 9):
The intervention group: HFNC preoxygenation for 4 minutes set at 60L/min of heated and humidified pure oxygen (fraction of inspired oxygen 100%, 37°C -OptiflowTM; Fisher & Paykel Healthcare, Auckland, New-Zealand). Large or medium nasal cannulae will be chosen according to the patient's nostril size to limit air contamination. Throughout the intubation procedure, HFNC will be maintained trying to achieve: -Continuous oxygenation while the patient will be spontaneously breathing during FOI, -Or apnoeic oxygenation during laryngoscopy for RSI The standard group: preoxygenation for 4 minutes with a face mask (which size will be adapted to fit the patient and ensure airtightness) connected to an Aisys CS2 ventilation system (General Electric, GE Healthcare, Oy, Finland). In this group, the ventilation system is set with 15 L/min of fresh gas, FiO2 = 100%, without inspiratory support or expiratory positive pressure.
-For RSI, the face mask (Economy, Intersurgical, Fontenay Sous Bois, France) will be removed after induction to enable intubation.
-For FOI the face mask (FibroxyTM, VBM, Sulz, Germany) will be kept in place throughout the intubation procedure with a 15L/min fresh gas flow, FiO2 = 100%, ensuring airtightness.
We fully agree that the device we are studying can deliver until 60 L/min and not (70 L/min). We modified the flow rate throughout the manuscript as well as in the Figure 1. Q4) Who will perform endotracheal intubation (attending physician, trainee, etc)? R4) Thank for your comment. The following information was inserted in the manuscript (Lines 14-16, page 9): In both groups, the first operator will be a senior or a junior supervised by a senior. All operators will have assisted a three half-day formation program so as to be familiar with this 3 oxygenation devices at the Nantes University Hospital simulation centre. Q5) They should explain more details regarding how to manage patient who develop desaturation during the study protocol? When to perform face mask ventilation? When to terminate the protocol? Because one of the main objective of the study is the number (or time) of manual FMV and this should have some standard criteria to initiate FMV R5) Thank you for this relevant comment. Indeed, the decision to use face mask ventilation is sometimes difficult to assess and to protocolized. That's why, our primary outcome is: The number of patients with at least one event among -desaturation ≤ 94% or need to use face mask ventilation for oxygen desaturation during intubation or the following 2 minutes -between groups. The primary outcome was built so as not to miss any events among oxygen desaturation or face mask ventilation (which can hide oxygen desaturation). As a result: -If the attending physician decides not to use face mask ventilation despite desaturation ≤ 94%, the event "desaturation" will lead the patient to be considered as "with an events" -In the same way, systematic face mask ventilation preventing desaturation ≤ 94% will also lead the patient to be considered as "with an events". We added precision regarding the primary outcome definition as well as a comment in the introduction and in the intervention sections with the recommendations for face ventilation in case of desaturation. Line 13-22, page 11: The patients will be classified in 2 groups: "No event" or "at least one event". -For RSI, the primary criterion will be assessed from the induction of general anaesthesia to 2 minutes following intubation.
-For FOI, the primary criterion will be assessed from the beginning of sedation to 2 minutes following intubation.
Arterial oxygen saturation will be evaluated by level of oxygen saturation measured by pulse oximetry (SpO2). The evaluation period of SpO2 will be extended to 2 minutes following intubation completion owing to possible delayed detection of desaturation with this device. Face mask ventilation will be noted if it occurs after general anaesthesia (RSI) or sedation (FOI) induction. From line 23, page 4 to line 2, page 5: According to the current guidelines, when the level of pulse oximetry (SpO2) drops below 95%, the operator has to interrupt intubation and focus on oxygenation (i.e. face mask ventilation).
[6] Nevertheless, face mask ventilation could be difficult or impossible in patients with anticipated DI, and could give rise to gastric insufflation or active gag reflex and provoke vomiting or aspiration. It also often requires deepening anaesthesia, leading to severe hypotension. As a result, to limit face mask ventilation during DI could also reduce adverse events, driving research effort in this field. Lines 17-23, page 9: The current guidelines advise to interrupt intubation to focus on oxygenation (i.e. face mask ventilation) for oxygen desaturation ≤ 94%.
[6] Nevertheless, the decision to proceed to face mask ventilation mainly depends on the progression of intubation procedure. Thus, mask ventilation is left at the discretion of the physician as well as the algorithm for rescue oxygenation. However, International recommendation will be presented to all of the investigators before the start of the study.
[7] The attending physician will be free to withdraw the oxygenation device if it disrupts the intubation process or the rescue oxygenation.
Outcome Q6) Page 13: In terms of severe complication please clarify the definition of severe desaturation that < 90% or < 80%? R6) Thank you for your precise reviewing. As suggested by reviewer #1 and yourself, we defined severe desaturation as < 80% (Line 6, page 13) Q7) Page 14: please check the definition of desaturation in the section of morbidity in the PACU whether it is defined < 90% or < 80%. R7) Thank you for this comment. We defined severe desaturation as < 80% (Line 5, page 14)
References for reviewer# 2: Reviewer: 3 Reviewer Name: Jörn Grensemann Q1) As far as I understand the protocol, the "standard" group receives preoxygenation with a nonrebreather mask with 15 L/min O2? By this method, a FiO2 of 1.0 cannot be delivered for preoxygenation and this method may not reflect the routine clinical practice with a half-closed rebreathing anesthesia circuit. In my opinion, the delivery of a FiO2 of 1.0 is mandatory especially in predicted difficult intubation. Please discuss why no anesthesia circuit is used in your study. R1) Thank you for your comment, we fully agree that Non-rebreather mask face mask would not have been able to deliver 100% FIO2. We have added precisions regarding the standard oxygenation device. Indeed, the control arm consists in a Face mask connected to an anesthesia ventilation system. The intervention section was modified as follows (Lines 4-12, page 9): The standard group: preoxygenation for 4 minutes with a face mask (which size will be adapted to fit the patient and ensure airtightness) connected to an Aisys CS2 ventilation system (General Electric, GE Healthcare, Oy, Finland). In this group, the ventilation system is set with 15 L/min of fresh gas, FiO2 = 100%, without inspiratory support or expiratory positive pressure.
